Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Sigma-Tau Ind Farm Riunite SpA and Debiopharm SA are developing istaroxime, the lead in a series of Na(+)/K(+)-ATPase inhibitors, for the potential treatment of cardiac failure. By September 2005, phase I/II trials of istaroxime were ongoing.
Wehrens
Xander Ht
XH
Baylor College of Medicine, Department of Molecular Physiology and Biophysics, Houston, TX 77030, USA. wehrens@bcm.edu
D000208:Acute Disease; D000818:Animals; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D005043:Etiocholanolone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D006333:Heart Failure / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D015394:Molecular Structure; D010330:Patents as Topic; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D004791:Enzyme Inhibitors; D005043:Etiocholanolone; D000254:Sodium-Potassium-Exchanging ATPase; C468128:Istaroxime